ProCE Banner Activity

Choosing a CDK4/6 Inhibitor in the Frontline Setting for HR+/HER2- Metastatic Breast Cancer: Highlighting the Importance of Shared Decision-Making

Clinical Thought

This activity provides an expert’s commentary on considerations with available CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer and the importance of shared decision-making with your patients.

Released: December 12, 2022

Expiration: December 11, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Jeremy M. Force

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Provided by

ProCE Banner

Supporters

This activity is supported by

Lilly

Disclosure

Jeremy Force, DO 
Consultant/speaker: Nanostring, Pfizer, Prime; researcher: Exact Sciences, G1 Therapeutics, Xilis.

Additional Information

Program Medium

This program has been made available online.